Table 5.
Discontinuation nights of withdrawn participants at months 1 and 4.
| Placebo (N=10) |
Zolpidem (N=9) |
|||||
|---|---|---|---|---|---|---|
| Month 1 | Scrn | Discon1* | Discon2 (N=8) | Scrn | Discon1 | Discon2 |
| TST | 380.05 (36.04) |
384.50 (84.47) |
404.38 (22.64) |
404.56 (60.29) |
378.56 (45.62) |
407.00 (35.98) |
| LPS | 26.90 (28.27) |
50.44 (51.37) |
51.50 (77.51) |
33.28 (17.89) |
27.44 (31.85) |
23.056 (15.94) |
| WASO | 79.95 (31.22) |
63.438 (63.09) |
31.50 (10.55) |
88.89 (51.08) |
78.67 (50.65 |
59.72 (33.79) |
| Placebo (N=3) |
Placebo (N=2) |
|||||
|---|---|---|---|---|---|---|
| Month 4 | Scrn | Discon1 | Discon2 | Scrn | Discon1 | Discon2 |
| TST | 380.05 (36.04) |
341.33 (95.53) |
367.00 (116.32) |
404.56 (60.29) |
397.50 (2.12) |
421.50 (3.54) |
| LPS | 26.90 (28.27) |
17.67 (14.29) |
26.17 (13.38) |
33.28 (17.89) |
11.25 (12.37) |
4.75 (3.89) |
| WASO | 79.95 (31.22) |
125.00 (102.98) |
97.67 (111.90) |
88.89 (51.08) |
77.00 (10.61) |
56.00 (4.95) |
Data means (SD) in minutes. *indicates the withdrawal of 2 participants prior to discon2, both due to noncompliance. Discon, discontinuation night; LPS, latency to persistent sleep; Scrn, screen night; TST, total sleep time; WASO, wake after sleep onset.